

Dolores J. Schendel, PhD

(*1947)

Institute of Molecular Immunology
GSF National Research Center for Environment and Health

Head of Institute

Marchioninstr. 25, 81377 München, Germany
Tel: +49 89 7099 301
Email: schendel@gsf.de



Curriculum vitae

1974 - 1975 National Institutes of Health Post-doctoral Fellowship, University College London, England (Dept. Prof. N.A. Mitchison)

1976 - 1978 Research Associate, Sloan-Kettering Institute for Cancer Research, New York, New York (Dept. Prof. B. Dupont)

1978 Associate, Sloan-Kettering Institute for Cancer Research, New York, New York (Dept. Prof. B. Dupont)

1978 - 1986 Scientific Assistant, Institute of Immunology, Ludwig-Maximilians-University Munich (Director: Prof. G. Riethmüller)

1986 - 1996 University Professor (C2), Institute of Immunology, Ludwig-Maximilians-University Munich

1996 - 1998 University Professor (C3) Institute of Immunology, Ludwig-Maximilians- University Munich

since 1998 Acting Director of the Institute (C4), Institute of Molecular Immunology GSF – National Research Center for Environment and Health, Munich

since 1998 University Professor, Ludwig-Maximilians-University Munich

Activities in the scientific community, honors, awards

since 1999: Vice Speaker of Sonderforschungsbereich SFB 455

since 1999: Member of the Steering Board Wilhelm-Vaillant Stiftung

since 2001: Member of the Scientific Committee HZI Braunschweig

since 2001: Center Coordinator; “Programm - orientierte Förderung” of the Helmholtz Society Programme “Infection and Immunity”

since 2004: Member of the “DFG – Fachkolleg “Mikrobiologie, Virologie and Immunology”

since 2004: Member of the *Fachausschuss der Deutschen Krebshilfe “Klinische Forschung, kliniknahe Grundlagenforschung”*

since 2005: Vice Speaker of Sonderforschungsbereich SFB-TR 36

since 2007: Study Panel Member of the European Research Council, EU Brussels

Research fields

- The major research area of the group is defining the molecular and cellular basis of anti-tumor immunity, with particular emphasis on T cell recognition. Based on these findings new immuno-therapies are developed for clinical trials in cooperation with the local universities of Munich.

Selected publications

Engels B, Nössner E, Frankenberger B, Blankenstein T, **Schendel DJ**, Uckert W. Redirecting human T lymphocytes towards renal cell carcinoma-specificity by retroviral transfer of T cell receptor genes. *Human Gene Ther* 16(7):799-810, 2005.

Frankenberger B, Pohla H, Noessner E, Willimsky G, Papier B, Pezzutto A, Koop J, Oberneder R, Blankenstein T, **Schendel DJ**. Influence of CD80, IL-2 and IL-7 expression in human renal cell carcinoma on the expansion, function and survival of tumor-specific cytotoxic T lymphocytes. *Clin Cancer Res* 11(5): 1733-1742, 2005.

Falk CS, Noessner E, Weiss EH, **Schendel DJ**. Retaliation against tumor cells showing aberrant HLA expression using lymphokine activated killer (LAK)-derived T cells. *Cancer Res* 62 (2): 480-487, 2002.

Becker C, Pohla H, Frankenberger B, Assenmacher M, **Schendel DJ**, Blankenstein T. Adoptive tumor therapy with T lymphocytes enriched through an IFN γ capture assay. *Nature Med* 7(10): 1159-1162, 2001.

Jantzer P, **Schendel DJ**. Human renal cell carcinoma antigen-specific cytotoxic T lymphocytes: antigen-driven selection and long-term persistence in vivo. *Cancer Res* 58: 3078-3086, 1998.